Condition: NSCLC (Non-small Cell Lung Cancer) · Sponsor: Tau Medical Australia Pty Ltd
This study aims to evaluate the safety of the CAROL device for treating lung tumors in patients diagnosed with non-small cell lung cancer (NSCLC) with tumor size ≤ 2 cm (cT1b). The primary objective is to assess safety by monitoring and grading adverse events using the CTCAE v5.0 criteria at one month following the procedure.
This description comes directly from the study's public registry record.
Daniel Steinfort, MD, PhD · +62 407 331 446 · Daniel.Steinfort@mh.org.au
Jaeyoung Seo · +82 10 4844 3203 · sjy@tau-medical.com
Always discuss trial participation with your own doctor first.
| Royal Melbourne Hospital | Melbourne, Victoria, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07122258